| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adolescent sarcoidosis mimicking malignant lymphoma
|
Kemps, Paul G
|
|
|
4 |
6 |
p. e450
|
artikel
|
| 2 |
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
|
Nanchahal, Jagdeep
|
|
|
4 |
6 |
p. e407-e416
|
artikel
|
| 3 |
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
|
Boekel, Laura
|
|
|
4 |
6 |
p. e417-e429
|
artikel
|
| 4 |
Combination therapies in rheumatoid arthritis—choose your partner carefully
|
Rubbert-Roth, Andrea
|
|
|
4 |
6 |
p. e376-e377
|
artikel
|
| 5 |
Correction to Lancet Rheumatol 2022; 4: e262–73
|
|
|
|
4 |
6 |
p. e392
|
artikel
|
| 6 |
Early-stage Dupuytren's disease treatment; a promising next step?
|
Selles, Ruud
|
|
|
4 |
6 |
p. e377-e378
|
artikel
|
| 7 |
Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases
|
Sparks, Jeffrey A
|
|
|
4 |
6 |
p. e380-e382
|
artikel
|
| 8 |
Exercise over analgesics for osteoarthritis in the UK
|
The Lancet Rheumatology,
|
|
|
4 |
6 |
p. e375
|
artikel
|
| 9 |
Fabian Proft: family, equity, and the future of rheumatology
|
Richards, Jennifer
|
|
|
4 |
6 |
p. e394
|
artikel
|
| 10 |
Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
|
Connolly, Caoilfhionn M
|
|
|
4 |
6 |
p. e382-e384
|
artikel
|
| 11 |
Immunosuppression and SARS-CoV-2 breakthrough infections
|
Kim, Alfred H J
|
|
|
4 |
6 |
p. e379-e380
|
artikel
|
| 12 |
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
|
Haberman, Rebecca H
|
|
|
4 |
6 |
p. e384-e387
|
artikel
|
| 13 |
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
|
Piga, Matteo
|
|
|
4 |
6 |
p. e441-e449
|
artikel
|
| 14 |
Research in Brief
|
Thorley, Jennifer
|
|
|
4 |
6 |
p. e393
|
artikel
|
| 15 |
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial
|
Fleischmann, Roy
|
|
|
4 |
6 |
p. e395-e406
|
artikel
|
| 16 |
Sulfasalazine: a risk factor for severe COVID-19?
|
Konig, Maximilian F
|
|
|
4 |
6 |
p. e388-e389
|
artikel
|
| 17 |
Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
|
Coates, Laura C
|
|
|
4 |
6 |
p. e390-e391
|
artikel
|
| 18 |
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
|
Widdifield, Jessica
|
|
|
4 |
6 |
p. e430-e440
|
artikel
|
Tijdschrift beschrijving